ReviewAnnals of medicine and surgery (2012)2025
Umbilical cord blood: a comprehensive review of protective and restorative properties in clinical applications - a narrative review.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stem cell-based therapies in pediatric disorders: translational advances, unresolved challenges, and future horizons.Stem cell research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Umbilical cord blood has emerged as a valuable biological resource rich in hematopoietic stem and progenitor cells, offering promising therapeutic potential in regenerative medicine, hematologic disorders, and immune modulation. Compared to bone marrow and peripheral blood stem cells, UCB demonstrates several clinical advantages, including lower risk of graft-versus-host disease (GVHD), increased tolerance for human leukocyte antigen (HLA) mismatch, and rapid availability. Transplantation success rates with UCB have improved significantly, with recent studies reporting overall survival rates of 60-70% in pediatric hematopoietic stem cell transplant recipients and 55-65% in adult recipients, particularly in malignant conditions. The incidence of acute GVHD following UCB transplantation ranges from 20% to 40%, while chronic GVHD occurs in approximately 10-20% of cases - lower than rates observed with other stem cell sources. Moreover, UCB-derived stem cells are being investigated for their regenerative and immunomodulatory capabilities in conditions such as cerebral palsy, type 1 diabetes, and ischemic injury, with early-phase trials showing encouraging safety and efficacy profiles. Despite these advancements, disparities in cost-effectiveness and accessibility remain pressing issues. Public cord blood banks offer greater equity in access and have facilitated most unrelated transplants, whereas private banks, often costly, primarily serve families for autologous use with limited clinical indication. This review provides a comprehensive analysis of the biological underpinnings, clinical applications, and outcomes associated with UCB-based therapies, while highlighting ongoing challenges in global access, standardization, and therapeutic scalability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.